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Abstract
Purpose This multicenter phase 2 study assessed the
tolerability and eYcacy of motesanib, an oral inhibitor of
Kit, platelet-derived growth factor receptor (PDGFR), and
vascular endothelial growth factor receptors (VEGFR), in
patients with imatinib-resistant gastrointestinal stromal
tumors (GIST).
Methods Patients with advanced GIST who failed imatinib
mesylate after ¸8 weeks of treatment with ¸600 mg daily
received motesanib 125 mg orally once daily continuously
for 48 weeks or until unacceptable toxicity or disease
progression occurred. The primary endpoint was conWrmed
objective tumor response per RECIST and independent
review. Secondary endpoints included progression-free sur-
vival (PFS), time to progression (TTP); objective response
by 18FDG-PET and by changes in tumor size and/or density
(Choi criteria); pharmacokinetics and safety.
Results In the patients evaluable for response (N =1 0 2 ) ,
the objective response rate was 3%; 59% of patients
achieved stable disease, with 14% achieving durable stable
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disease ¸24 weeks; 38% had disease progression. Higher
objective response rates were observed per 18FDG-PET
(N = 91) (30%) and Choi criteria (41%). The median PFS
was 16 weeks (95% CI = 14–24 weeks); the median TTP
was 17 weeks (95% CI = 15–24 weeks). The most common
motesanib treatment-related grade 3 adverse events
included hypertension (23%), fatigue (9%), and diarrhea
(5%). Motesanib did not accumulate with daily dosing.
Conclusions In this study of patients with imatinib-resis-
tant GIST, motesanib treatment resulted in acceptable toler-
ability and modest tumor control as evident in the
proportion of patients who achieved stable disease and
durable stable disease.
Keywords Angiogenesis · GIST · Imatinib · Kit receptor · 
Motesanib · VEGF receptor
Introduction
Until the success of imatinib mesylate, patients with met-
astatic gastrointestinal stromal tumors (GIST) had a dis-
mal prognosis since no systemic therapy provided
clinical beneWt. Surgery is the initial therapy for patients
with primary resectable GIST; however, approximately
half of all patients eventually develop metastatic disease
[1]. Mutually exclusive gain-of-function mutations in the
KIT proto-oncogene (occurring in 85–90% of GISTs) or
in the platelet-derived growth factor receptor  gene
(PDGFRA; about 5% of tumors) play a fundamental role
in the development of GISTs [2]. Imatinib, a selective
inhibitor of Kit and PDGFR kinase activity, has been
shown to substantially improve clinical outcomes in
patients with advanced disease [3, 4]. However, approxi-
mately 14% of treated patients exhibit primary imatinib
resistance, which is associated with shortened survival,
and many if not all, develop secondary resistance after an
initial response [3,  4]. Sunitinib malate, a multikinase
inhibitor, has recently been demonstrated to be eVective
as second-line therapy in imatinib-resistant GIST [5]. The
duration of secondary disease control with sunitinib is
much shorter though than the initial control with imati-
nib, despite considerable toxicity, indicating that alterna-
tive therapies are needed [5].
Motesanib is a highly selective, oral inhibitor of VEGF
receptors (VEGFR) 1, 2, and 3; and PDGFR (IC50,
84 nmol/L). In addition, motesanib potently inhibits wild-
type Kit in vitro (IC50, 8 nmol/L) [6]. Motesanib has also
been shown to inhibit autophosphorylation of a number of
clinically relevant primary Kit mutants with greater
potency than imatinib and has demonstrated activity against
some imatinib-resistant mutants (e.g., Y823D and D816H)
[7], suggesting that it may have antitumor activity in
imatinib-resistant GIST. In preclinical studies, motesanib
induced signiWcant tumor regression in xenograft models of
human breast carcinoma [8], nonsmall cell lung cancer [9],
medullary thyroid cancer [10], and epidermoid and colon
carcinoma [6, 11]. When tumor blood vessel density was
investigated the results showed that motesanib treatment
selectively targeted neovascularization indicating that the
observed antitumor eVect was mediated at least in part by
inhibition of angiogenesis. Motesanib did not inhibit the
proliferation of tumor cells in vitro [6, 8–10]. In the phase 1
Wrst-in-human study in solid malignancies, a motesanib
dose of 125 mg once daily was established as the maximum
tolerated dose. In that study, three patients with thyroid
cancer and one patient with leiomyosarcoma achieved a
partial response [12].
The aim of this study was to evaluate the tolerability and
eYcacy of motesanib, using diVerent methods for tumor
response measurement including Response Evaluation
Criteria in Solid Tumors (RECIST), Choi criteria [13, 14]
and  18Xuorodeoxyglucose positron emission tomography
(18FDG-PET) [15,  16], in patients with advanced GIST
who developed progressive disease (PD) or relapsed while
receiving imatinib therapy.
Methods
Eligibility criteria
Key inclusion criteria were age ¸18 years; histologically
conWrmed GIST (expressing CD117); disease progression
per RECIST during previous treatment with imatinib mes-
ylate ¸600 mg daily for ¸8 weeks, as per two indepen-
dently assessed prestudy computerized tomography (CT)
scans; imatinib treatment terminated at least 7 days before
study day 1; presence of at least one measurable (per
RECIST) and progressing tumor lesion not previously
treated with radiotherapy or embolization and evaluable
by CT scan or magnetic resonance imaging (MRI);
Karnofsky performance status ¸60; and adequate hepatic,
renal, and cardiac function. Key exclusion criteria were
prior malignancy (other than GIST, in situ cervical can-
cer, or basal cell cancer of the skin) unless treated with
curative intent and without evidence of disease for
¸3 years; uncontrolled hypertension (systolic >  145 mmHg
or diastolic > 85 mmHg), or history of arterial or deep
vein thrombosis (including pulmonary embolus) within
1 year of study day 1; and prior treatment with VEGF or
KIT (except imatinib) inhibitors. The study was approved
by the institutional review board of each participating
institution, and all patients provided written informed
consent before any study-related procedures were
performed.Cancer Chemother Pharmacol (2011) 68:69–77 71
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Study design and treatment
This was a phase 2, multicenter, open-label, single-arm
study. The primary endpoint was objective response (partial
response [PR] or complete response [CR]) per RECIST, as
determined by central independent review. Secondary end-
points prospectively included the duration of response,
progression-free survival (PFS), time to disease progression
(TTP), time to response, and overall survival; objective
response by 18FDG-PET at week 8 and by changes in target
tumor size and/or density (HounsWeld units) at week 8
(Choi response criteria) [13,  14]; pharmacokinetic (PK)
parameters of motesanib, and adverse events.
After a ¸7-day washout of imatinib prior to study day 1,
motesanib 125 mg (Amgen Inc., Thousand Oaks, CA, USA)
was self-administered orally once daily without interruption
until disease progression or intolerance occurred, for a maxi-
mum of 48 weeks. Patients deriving clinical beneWt at
48 weeks could enroll in an extension study.
Adverse events were recorded from day 1 through to
30 days after the last dose of motesanib and were graded
based on the Common Terminology Criteria for Adverse
Events (CTCAE) Version 3.0.
Tumor response
Tumor measurements were performed within 21 days of
study day 1 (baseline) and after 8, 16, 24, 32, 40, and
48 weeks (§4 days) of treatment using nonenhanced and
contrast-enhanced CT. Measurable target lesions were eval-
uated for response using RECIST. Objective responses
were conWrmed by a second CT scan ¸4 weeks later.
18FDG-PET scans and tumor size and density measure-
ments per CT were obtained at baseline and after 8 weeks.
All tumor responses were reviewed retrospectively by an
independent central panel.
Objective response by 18FDG-PET at week 8 was deW-
ned as a >25% decrease in the average standardized uptake
value (SUV) in all RECIST target lesions compared with
the average baseline SUV of all RECIST target lesions
[17]. Objective response by Choi response criteria [14] was
deWned as ¸10% decrease in the sum of longest diameters
(SLD) and/or ¸15% decrease in the average target tumor
density using the RECIST target lesions on CT scans at
week 8, compared with baseline.
Pharmacokinetics
Blood samples for intensive PK were collected by design
from up to 20% of patients on study days 1 and 28 at pre-
dose, and 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h after motesanib
diphosphate administration from patient. Trough PK blood
samples were collected at scheduled visits every 2 weeks
(§4 days) for the Wrst 16 weeks and then every 4 weeks
(§4 days). Motesanib concentrations in the plasma were
analyzed at using a validated liquid chromatography assay
coupled with tandem mass spectrometry (CEDRA Corpora-
tion, Austin, TX). The lower limit of quantiWcation was
0.2 ng/mL. Pharmacokinetic parameters were estimated
from plasma concentration–time data using standard non-
compartmental methods (WinNonlin Professional version
4.1e, Pharsight Corp., Mountain View, CA).
Statistical analysis
The planned sample size was 100, which would produce a
2-sided 95% conWdence interval (CI) of 5–18% for the
objective response rate if a point estimate of 10% was
observed. Primary and secondary eYcacy analyses were
performed on the prospectively deWned per-protocol analy-
sis set (all patients from the full analysis set who had pre-
study disease progression per RECIST and according to
independent review). Additional sensitivity analyses were
conducted on the full analysis set (all patients who received
¸1 dose of motesanib). EYcacy analysis per 18FDG-PET or
Choi response criteria was also performed on the evaluable
patient population (all patients with a baseline and week-8
18FDG-PET or CT scan, respectively). Objective response
by 18FDG-PET and Choi criteria assessed at week 8 were
correlated with PFS using RECIST to evaluate progression
(Cox proportional hazards model) to assess the predictive
value of early changes in tumor density and/or size.
Reported P-values were not adjusted for multiple compari-
sons. Duration of response was the time from Wrst con-
Wrmed objective response to the Wrst PD assessment per
RECIST or death if due to disease progression; PFS was the
time from study day 1 to the date of conWrmed disease pro-
gression or death regardless of cause; TTP was the time
from study day 1 to the date when physical or radiological
evidence of disease progression is determined, or death if
due to progression; and overall survival was the time from
study day 1 to the date of death due to any reason.
Results
Patient characteristics and disposition
The study enrolled 138 patients with advanced imatinib-
resistant GIST from 29 centers in 7 countries (October
2004 through July 2005). In order to ensure that at least 100
enrolled patients would be considered evaluable, overen-
rollment of 20% was targeted. At the time of enrollment
closure, 20 more evaluable patients had been enrolled and
an additional 18 patients who were in screening at that time
were also evaluable and enrolled.72 Cancer Chemother Pharmacol (2011) 68:69–77
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Baseline demographics and clinical characteristics are
summarized in Table 1. All patients had received imatinib
at a dose of at least 600 mg/day for ¸8 weeks (78%
received a daily dose of 800 mg); median duration of
imatinib therapy was 32.5 months. Thirty-eight percent of
patients had an objective response to imatinib therapy per
RECIST, and 28% had SD. All patients received ¸1 dose
of motesanib and were evaluated for safety and tolerability;
median duration of therapy was 16 weeks (range 0.3–52),
with 15 patients (9%) completing the scheduled 48-week
treatment period. Reasons for early therapy discontinuation
were as follows: disease progression (n = 79), adverse
events (n = 22), withdrawal of consent (n = 6), death
(n = 3), and other (n = 4). Based on the full analysis set,
77 patients died; for the remaining patients, median follow-
up was 12.8 months (minimum, 4.5; maximum, 23.4).
EYcacy
The response to therapy is summarized in Table 2. The
change from baseline in tumor measurement for individual
patients from the per-protocol analysis set is shown in
Fig. 1.
The time to RECIST response per independent review
was 7, 8, and 16 weeks for the three responders, with the
duration of response of 16, 40 (patient completed the
48-week treatment without observed disease progression),
and 16 weeks, respectively. The patient who achieved the
duration of response of 40 weeks continued motesanib in an
extension study. As of January 13, 2009, the patient has not
progressed per investigator assessment (censored duration
of response from the initial response: 177 weeks). Median
PFS time was 16 weeks (95% CI = 14–24), and 34% of
patients were progression-free at 24 weeks (Fig. 2). Median
TTP was 17 weeks (95% CI = 15–24). At the time of data
cutoV, 67 patients (56%; based on the per-protocol analysis
set) had died. The median overall survival for the per-pro-
tocol population was 64 weeks (95% CI = 49–88) (Fig. 3).
The objective response rate was 30% (95% CI = 20.5–40.2)
using 18FDG-PET at week 8 and the EORTC PET response
deWnition for the evaluable subset (N = 91). Using Choi
response criteria, the objective response rate at week 8 was
41% (95% CI = 31.5–51.4) in the evaluable population
(N =1 0 2 )  ( T a b l e2). Best tumor response per Choi criteria
is shown in Fig. 1. The estimated median TTP for evaluable
Choi responders was 22 weeks (95% CI = 16–24), com-
pared with 15 weeks (95% CI = 8–22) for nonresponders
(P = 0.35). Using Cox proportional hazard modeling in
evaluable patients, none of the three tumor response assess-
ment methods were predictive of PFS (RECIST, P =0 . 3 1 ;
18FDG-PET, P = 0.17; and Choi criteria, P =0 . 3 4 ) .
Safety
Nearly, all patients (92%) experienced at least one treat-
ment-related adverse event; 52% of these events were grade
1 or 2 and reversible. Thirty-seven patients (27%)
Table 1 Baseline demographics and clinical characteristics
a Primary resistance: failure to achieve stable disease in response to
imatinib or development of disease progression within 6 months of an
initial clinical response to imatinib. Secondary resistance: develop-
ment of one or more sites of disease progression after more than
6 months of clinical response to imatinib
All patients (N = 138)
Male/female, n (%) 84/54 (61/39)
Age years)
Median (range) 61 (25, 90)
¸65 years, n (%) 54 (39)
Karnofsky performance status, n (%)
100 33 (24)
90 63 (46)
80 22 (16)
70 14 (10)
60 6 (4)
Number of sites of disease, n (%)
1 51 (37)
2 55 (40)
3 27 (20)
¸45  ( 4 )
Imatinib resistance, n (%)a
Primary 47 (34)
Secondary 91 (66)
Prior chemotherapy, n (%)
None 117 (85)
1 Regimen 11 (8)
¸2 Regimens 10 (7)
Duration of Wrst imatinib therapy, n (%)
·6 months 34 (25)
>6 months 104 (75)
Total duration of imatinib therapy (months)
Median (range) 33 (4, 57)
Best response to initial imatinib, n (%)
Complete response 4 (3)
Partial response 48 (35)
Stable disease 39 (28)
Progressive disease 47 (34)
Highest imatinib dose administered (mg), n (%)
600 21 (15)
700 1 (1)
800 108 (78)
1,000 4 (3)
1,100 1 (1)
1,200 3 (2)Cancer Chemother Pharmacol (2011) 68:69–77 73
123
discontinued treatment due to an adverse event. The three
most common related grade 3 events were hypertension
(23%), fatigue (9%), and diarrhea (5%) (Table 3). There
were nine related grade 4 events, including one event of
hypertension (reversible posterior leucoencephalopathy
with sudden blindness syndrome; others were acute cardiac
failure, enterocutaneous Wstula, subarachnoid hemorrhage,
pulmonary embolism, pulmonary edema, respiratory failure,
Table 2 Tumor response to treatment with motesanib
a All patients who received at least one dose of motesanib and who had prestudy disease progression per RECIST as assessed by independent
review
b Ended motesanib treatment prior to the Wrst scheduled assessment of response
c DeWned as >25% decrease in average standardized uptake value (SUVmax) in all RECIST target lesions compared with the average SUVmax in
all RECIST target lesions at baseline (measured by independent reviewer)
d DeWned as ¸10% decrease in the sum of the longest diameter of the target lesions (identiWed by RECIST) and/or ¸15% decrease in the average
target tumor density using the RECIST target lesions compared with the average baseline density based on CT scans
Criteria and response All patients 
(N =1 3 8 )
Per-protocol analysis 
seta (N =1 2 0 )
RECIST/Choi evaluable 
patients (N =1 0 2 )
18FDG-PET evaluable 
patients (N =9 1 )
RECIST
ConWrmed RECIST response, n (%) 3 (2) 3 (3) 3 (3) 3 (3)
95% CI 0.5–6.2 0.5–7.1 0.6–8.4 0.7–9.3
ConWrmed partial response, n (%) 3 (2) 3 (3) 3 (3) 3 (3)
Stable disease, n (%) 70 (51) 60 (50) 60 (59) 55 (60)
Durable stable disease ¸24 weeks, n (%) 19 (14) 14 (12) 14 (14) 14 (15)
Progressive disease, n (%) 43 (31) 39 (33) 39 (38) 33 (36)
Not assessed, n (%)b 22 (16) 18 (15) 0 (0) 0 (0)
18FDG-PET at week 8c
Objective response, n (%) 28 (20) 27 (23) – 27 (30)
95% CI 13.9–28.0 15.4–31.0 20.5–40.2
Nonresponse, n (%) 110 (80) 93 (78) – 64 (70)
95% CI 72.0–86.1 69.0–84.6 59.8–79.5
Choi criteria at week 8d
Objective response, n (%) 45 (33) 42 (35) 42 (41) –
95% CI 24.9–41.1 26.5–44.2 31.5–51.4
Nonresponse, n (%) 93 (67) 78 (65) 60 (59) –
95% CI 58.9–75.1 55.8–73.5 48.6–68.5
Fig. 1 Maximum percent change from baseline in sum of longest
diameters (SLD) of target lesions per RECIST and independent review
in patients evaluable for response by RECIST or Choi criteria. Not
shown:  n = 1 progressive disease (new lesion; SLD unavailable).
Not included: 18 patients (from the per-protocol set) without tumor
response information (SLD measured prior to week 8). Changes in
SLD > 30% shown as stable disease represent unconWrmed PRs74 Cancer Chemother Pharmacol (2011) 68:69–77
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and peripheral ischemia; n = 1 each). One fatal grade 5
event due to myocardial infarction occurring on study day 2
was considered by the investigator to be possibly related to
treatment; of note, this patient had a number of pre-existing
and concurrent comorbidities. Several related events of spe-
ciWc clinical interest occurred, including thromboembolic
events, hemorrhage, anemia, and cardiac failure (Table 3).
There was one event each of cholecystitis (grade 1) and
pancreatitis (grade 3) considered unrelated by the investiga-
tor. Twenty-two deaths were recorded on study: disease
progression (n = 12), cardiac disorders (n = 4), aspiration
pneumonia (n = 2), deterioration of general condition
(n = 1), intestinal obstruction (n =2 ) ,  a n d  s e p s i s  ( n =1 ) .
Pharmacokinetics
Twenty-six patients had assessable intensive PK results.
Motesanib was rapidly absorbed after a single dose of
125 mg on day 1 with a median (range) tmax of 0.58 (0.25–
4.0) h, and after daily administration for 28 days (tmax 1.0
[0.42–4.0] h). Compared with day 1, mean values for Cmax,
AUC0–24, and trough concentrations at 24 h after dosing
(C24) on day 28 were slightly lower, indicating that motesa-
nib did not accumulate after daily administration (mean
ratios of day 28 to day 1 in the same patients: 0.89 [n = 27],
0.84 [n = 19], and 0.92 [n = 19], respectively). Mean C24
values suggest that a dose of 125 mg (or higher) would
provide continuous coverage above the concentration
that inhibits 50% of proliferation in human umbilical vein
endothelial cells in vitro (data on Wle; Amgen Inc., Thousand
Oaks, CA).
The day-1 PK parameters of motesanib were similar in
patients with partial or full gastrectomy (n = 8) and in
patients without gastrectomy (n = 19). However, in the gas-
trectomy cohort, the mean (SD) day 28 values for AUC0–24
(2.09 [1.48] vs. 2.53 [2.44] gh / m L )  a n d  C 24 (6.67 [3.64]
vs. 21.8 [37.3] ng/mL) were slightly lower and, based on
the mean concentration–time proWle, there was a slightly
faster elimination in the terminal phase (mean [SD] t1/2,z
4.42 [0.95] h vs. 5.45 [1.87] h). Substantially, shorter t1/2,z
values (>50% decrease) on day 28 were observed in only
four out of eight patients in the gastrectomy group.
Discussion
Treatment with motesanib, an investigational inhibitor of
VEGF receptors, PDGFR and Kit, resulted in clinical ben-
eWt, acceptable tolerability, and a PK proWle similar to what
has been observed in a previous monotherapy study [12],
indicating no accumulation with repeat daily dosing. While
the number of patients in the gastrectomy subgroup was
small, the data showed that motesanib PK proWles were
similar in patients with and without gastrectomy.
Currently, sunitinib is the only approved multitargeted
kinase inhibitor in this disease setting. Although comparing
study results outside of a head-to-head setting is diYcult, a
few points of comparison between the large randomized,
Fig. 2 Kaplan–Meier estimate 
of progression-free survival 
(PFS) time during treatment 
with motesanib (analysis in-
cludes all patients in the full 
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disease progression per RECIST 
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sent 95% CIs of the Kaplan–
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controlled study of sunitinib [5] and the study described
herein are worth mentioning. Both studies focused on
patients with imatinib-resistant GIST. In the sunitinib
study, which enrolled patients who had failed any dose of
prior imatinib therapy or were imatinib intolerant, the
RECIST response rate was relatively low (7%), but 58% of
patients achieved SD and 24.2% achieved clinical beneWt
(objective response plus durable SD [¸22 weeks]); the
median PFS and TTP was 24.1 and 27.3 weeks, respec-
tively [5]. In comparison, in the study described here, the
RECIST response rate (based on patients evaluable for
response, N = 102) was only 3%; however, 59% of patients
achieved SD, including 14% with durable SD ¸ 24 weeks,
and 17% achieved clinical beneWt (i.e., conWrmed CR or PR
or durable SD ¸ 24 weeks), indicating antitumor activity
after failure of high-dose imatinib. The median PFS and
TTP was only 16 and 17 weeks, respectively.
Since the availability of targeted therapies for patients
with GIST, increasing concern has been raised over the
suitability of RECIST to estimate the proportion of patients
likely to beneWt from therapy, particularly in the early
phase of treatment, as targeted therapies may be more
likely to induce more modest, yet sustained, reductions in
tumor volume or progression arrest, which can be clinically
meaningful [18]. Several reports have shown that 18FDG-
PET not only is highly sensitive in detecting early response
to imatinib therapy but also predicts the long-term response
of GISTs to imatinib treatment [15, 16]. In our study, the
tumor response rate per 18FDG-PET at week 8 was 30% in
the evaluable population, compared with a 3% response
rate per RECIST. Choi response criteria, which were only
recently validated in a single-center study in patients with
GIST treated with imatinib as initial tyrosine kinase inhibi-
tor therapy, are based on a combination of tumor size and
density measurements by CT [13] and have been shown by
Choi et al. [14] and Benjamin et al. [19] to be more sensi-
tive in identifying 18FDG-PET responders than RECIST.
Furthermore, the same investigators reported that Choi
response criteria have been shown to correlate signiWcantly
with TTP and disease-speciWc survival, compared with
RECIST [19]. In the evaluable population of our study,
41% had a tumor response at week 8 based on Choi criteria,
but the diVerence in TTP between Choi criteria responders
and nonresponders was not signiWcant (P = 0.35). How-
ever, it is noteworthy that only criteria of RECIST deter-
mined progression and not the progression criteria of Choi.
Importantly, as can be seen in Fig. 1, 11 (26%) of the Choi
responders (N = 42) were RECIST progressors at initial
assessment. Comparison of response with survival was not
planned in the protocol.
Another limitation of the study is the fact that it was not
powered for the exploratory endpoints discussed above.
Therefore, deWnitive conclusions about the comparison of
tumor response using RECIST, 18FDG-PET, or Choi
response criteria in this population cannot be reached.
However, the results contribute to the ongoing discussion
about the insensitivity of RECIST in determining tumor
response to targeted therapies in patients with GIST
[14, 19]. Future, adequately powered studies may provide
more insight.
Most motesanib-related adverse events were mild and
reversible, and consistent with those reported earlier in
monotherapy settings [12,  20]. Hypertension, a known
adverse event of VEGFR inhibitors [21], occurred most fre-
quently (including one grade 4 event) but was generally
manageable with antihypertensive therapy. Other related
events, in particular hemorrhage and thromboembolic
events, have been reported previously for other VEGFR
Table 3 Treatment-related adverse events occurring in ¸5% of
patients and treatment-related adverse events of speciWc interest
a Reversible posterior leucoencephalopathy syndrome
b Two patients experienced both a thromboembolic event and a car-
diac disorder: myocardial infarction/acute cardiac failure and grade 4
coronary artery arteriosclerosis; grade 4 cardiac failure and grade 2
ischemic stroke. One grade 5 event of myocardial infarction occurred
c Patients were not monitored with serial thyroid-stimulating hormone
levels during the study
All patients 
(N = 138)
Grade 3 Grade 4
Treatment-related adverse events, n (%)
Diarrhea 67 (49) 7 (5) 0
Hypertension 65 (47) 32 (23) 1 (1)a
Fatigue 41 (30) 12 (9) 0
Headache 34 (25) 4 (3) 0
Nausea 28 (20) 3 (2) 0
Anorexia 22 (16) 5 (4) 0
Dysphonia 16 (12) 0 0
Vomiting 15 (11) 2 (1) 0
Asthenia 14 (10) 2 (1) 0
Weight decreased 13 (9) 4 (3) 0
Flatulence 11 (8) 0 0
Dehydration 8 (6) 5 (4) 0
Dizziness 8 (6) 1 (1) 0
Abdominal distension 7 (5) 2 (1) 0
Abdominal pain upper 7 (5) 1 (1) 0
Treatment-related adverse events of speciWc interest, n (%)
Thromboembolic eventsb 7 (5) 1 (1) 3 (2)
Hemorrhage 2 (1) 1 (1) 1 (1)
Impaired wound healing 1 (1) 1 (1) 0
Cardiac failureb 2 (1) 1 (1) 1 (1)
Anemia 2 (1) 0 0
Thrombocytopenia 1 (1) 0 0
Hypothyroidismc 1 (1) 1 (1) 076 Cancer Chemother Pharmacol (2011) 68:69–77
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inhibitors, indicating a class eVect [21]. Three patients (2%)
developed hypothyroidism; one of these events was consid-
ered related to treatment. Hypothyroidism has recently been
described as a complication associated with sunitinib and
imatinib treatment [5, 22–25]. Close monitoring of thyroid-
stimulating hormone levels in patients receiving multikin-
ase inhibitors is probably warranted.
In conclusion, in this study of patients with imatinib-
resistant GIST, treatment with motesanib resulted in clini-
cal beneWt with acceptable tolerability. Although antitumor
activity was evident based on the proportion of patients
who achieved PR and durable SD and toxicity was rela-
tively mild, thus suggesting that further study of motesanib
in patients with imatinib-resistant GIST is warranted, the
insuYcient overall eYcacy does not support further devel-
opment of motesanib in GIST.
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